<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243060</url>
  </required_header>
  <id_info>
    <org_study_id>NEY-1413</org_study_id>
    <nct_id>NCT01243060</nct_id>
  </id_info>
  <brief_title>Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance</brief_title>
  <official_title>Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern California Institute of Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern California Institute of Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, there has been increased focus on cognitive side effects of sleep-inducing
      medications that may contribute to unusual behavior during unexpected awakenings during the
      night. Concerns regarding these side effects have led to a class Food and Drug Administration
      (FDA) warning for all sleep-inducing medications. Almorexant is an experimental
      sleep-inducing medication in a new class of medications that is being extensively developed
      by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in
      the brain that function with proteins called hypocretins. The goal of this study is to
      evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep
      aid) or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 216 healthy volunteers will be enrolled to participate in the 10 day study. After
      screening procedures have been completed (at SFVAMC), Days 1 - 7 will take place in subjects'
      homes, where their sleep/wake activity will be monitored. Days 8 - 10 will take place at
      Moffitt Hospital. On Day 10, subjects will take one dose of either almorexant 100mg,
      almorexant 200mg, zolpidem 10mg, or placebo. Cognitive tests will be administered to subjects
      throughout Day 10. Subjects will return for follow-up safety labs within 5 - 12 days of
      dosing with study medication. Based on animal studies, it is anticipated that subjects who
      take almorexant will be less cognitively impaired than those who take zolpidem.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A comparison between dosing groups on performance on neurocognitive measures</measure>
    <time_frame>Within a 7-hour window post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Almorexant 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a one-time dose of Almorexant 100mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Almorexant 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a one-time dose of Almorexant 200mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a one-time dose of Zolpidem 10mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a one-time dose of Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Almorexant</intervention_name>
    <description>100mg</description>
    <arm_group_label>Almorexant 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Almorexant</intervention_name>
    <description>200mg</description>
    <arm_group_label>Almorexant 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem 10mg</intervention_name>
    <description>10mg</description>
    <arm_group_label>Zolpidem</arm_group_label>
    <other_name>Ambien</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One-time dose of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To participate in the study, participants must:

          -  Be between the ages of 19 and 39

          -  Be in good physical health

          -  Be a good sleeper with consistent bedtimes and wake times

          -  Not have problems falling or staying asleep

          -  Be a non-smoker

          -  Meet our other study criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Neylan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Institute of Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Veterans Affairs Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern California Institute of Research and Education</investigator_affiliation>
    <investigator_full_name>Thomas C. Neylan, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sleep Aid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

